Fasudil Ameliorates Disease Progression in Experimental Autoimmune Encephalomyelitis, Acting Possibly Through Antiinflammatory Effect

CNS Neuroscience and Therapeutics

Volumn 18, Issue 11, 2012, Pages 909-917

  Hou, Shao Wei ^a   Liu, Chun Yun ^a   Li, Yan Hua ^a   Yu, Jie Zhong ^a   Feng, Ling ^a   Liu, Yue Ting ^a   Guo, Ming Fang ^a   Xie, Yong ^a   Meng, Jian ^a   Zhang, Hai Fei ^a   Xiao, Bao Guo ^b   Ma, Cun Gen ^a,c  

^a SHANXI DATONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Antiinflammation; Experimental autoimmune encephalomyelitis; Fasudil

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID 2 RECEPTOR; FASUDIL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; NERVE GROWTH FACTOR; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG MECHANISM; FEMALE; MACROPHAGE; MICROGLIA; MOUSE; MYELINATION; NONHUMAN; PHENOTYPE; RECEPTOR UPREGULATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA;

EID: 84868195009     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12002     Document Type: Article

References (51)

1. Tselis A. Evidence for viral etiology of multiple sclerosis. Semin Neurol 2011;31:307-316.
2. Stadelmann C, Wegner C, Brück W. Inflammation, demyelination, and degeneration - recent insights from MS pathology. Biochim Biophys Acta 2011;1812:275-282.
3. Tuohy VK, Yu M, Yin L, et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1998;164:93-100.
4. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747.
5. Guilluy C, Garcia-Mata R, Burridge K. Rho protein crosstalk: another social network? Trends Cell Biol 2011;21:718-726.
6. Bao W, Hu E, Tao L, et al. Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 2004;61:548-558.
7. Slotta JE, Laschke MW, Menger MD, Thorlacius H. Rho-kinase signalling mediates endotoxin hypersensitivity after partial hepatectomy. Br J Surg 2008;95:976-984.
8. Ding RY, Zhao DM, Zhang ZD, Guo RX, Ma XC. Pretreatment of Rho kinase inhibitor inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in mice. J Surg Res 2011;171:e209-e214.
9. Pierot L, Aggour M, Moret J. Vasospasm after aneurysmal subarachnoid hemorrhage: recent advances in endovascular management. Curr Opin Crit Care 2010;16:110-116.
10. Rikitake Y, Kim HH, Huang Z, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005;36:2251-2257.
11. Hara M, Takayasu M, Watanabe K, et al. Protein kinase inhibition by fasudil hydrochloride promotes neurological recovery after spinal cord injury in rats. J Neurosurg 2000;93:94-101.
12. Wang L, Kamath A, Frye J, Iwamoto GA, Chun JL, Berry SE. Aorta-derived mesoangioblasts differentiate into the oligodendrocytes by inhibition of the Rho kinase signaling pathway. Stem Cells Dev 2012;21:1069-1089.
13. Wang H, Rusielewicz T, Tewari A, Leitman EM, Einhenber S, Melendez-Vasquez CV. Myosin II is a negative regulator of oligodendrocyte morphological differentiation. J Neurosci Res 2012;90:1547-1556.
14. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4:387-398.
15. Wang Z, Liu D, Wang F, et al. Saturated fatty acids activate microglia via Toll-like receptor 4/NF-κB signalling. Br J Nutr 2012;107:229-241.
16. Bhaskar S, Shalini V, Helen A. Quercetin regulates oxidized LDL induced inflammatory changes in human PBMCs by modulating the TLR-NF-κB signaling pathway. Immunobiology 2011;216:367-373.
17. Woods DC, White YA, Dau C, Johnson AL. TLR4 activates NF-κB in human ovarian granulosa tumor cells. Biochem Biophys Res Commun 2011;409:675-680.
18. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009;29:13435-13444.
19. Mahbub S, Deburghgraeve CR, Kovacs EJ. Advanced age impairs macrophage polarization. J Interferon Cytokine Res 2012;32:18-26.
20. Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab 2005;25:477-484.
21. Teng FY, Tang BL. NF-kappaB signaling in neurite growth and neuronal survival. Rev Neurosci 2010;21:299-313.
22. Heasman SJ, Ridley AJ. Multiple roles for RhoA during T cell transendothelial migration. Small Gtpases 2010;1:174-179.
23. Takesono A, Heasman SJ, Wojciak-Stothard B, Garg R, Ridley AJ. Microtubules regulate migratory polarity through Rho/ROCK signaling in T cells. PLoS ONE 2010;5:e8774.
24. Mogi M, Kondo A. Down-regulation of NF-kappaB led to up-regulation of NGF production in mouse osteoblasts. J Immunoassay Immunochem 2010;31:92-101.
25. Ellrichmann G, Thöne J, Lee DH, Rupec RA, Gold R, Linker RA. Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation. J Neuroinflammation 2012;9:15.
26. Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 2011;11:807-822.
27. Prendergast CT, Anderton SM. Immune cell entry to central nervous system-current understanding and prospective therapeutic targets. Endocr Metab Immune Disord Drug Targets 2009;9:315-327.
28. Herz J, Zipp F, Siffrin V. Neurodegeneration in autoimmune CNS inflammation. Exp Neurol 2010;225:9-17.
29. Bowen JL, Olson JK. Innate immune CD11b+Gr-1+ cells, suppressor cells, affect the immune response during Theiler's virus-induced demyelinating disease. J Immunol 2009;183:6971-6980.
30. Slaney CY, Toker A, La FA, Backstrom BT, Harper JL. Naïve blood monocytes suppress T-cell function. A possible mechanism for protection from autoimmunity. Immunol Cell Biol 2011;89:7-13.
31. Zhu B, Bando Y, Xiao S. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 2007;179:5228-5237.
32. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005;5:641-654.
33. Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010;116:5738-5747.
34. Kropf P, Freudenberg MA, Modolell M, et al. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun 2004;72:1920-1928.
35. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011;11:802-807.
36. Moliné-Velázquez V, Cuervo H, Ortega MC, Clemente D, de Castro F. Myeloid-derived suppressor cells limit the inflammation by promoting T lymphocyte apoptosis in the spinal cord of a murine model of multiple sclerosis. Brain Pathol 2011;21:678-691.
37. Wang XP, Chen YG, Qin WD, et al. Arginase I attenuates inflammatory cytokine secretion induced by lipopolysaccharide in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2011;31:1853-1860.
38. Ckless K, van der Vliet A, Janssen-Heininger Y. Arginase modulates NF-κB activity via a nitric oxide-dependent mechanism. Am J Respir Cell Mol Biol 2007;36:645-653.
39. Maresz K, Pryce G, Ponomarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007;13:492-497.
40. Palazuelos J, Davoust N, Julien B, et al. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 2008;283:13320-13329.
41. Cabral GA, Harmon KN, Carlisle SJ. Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Adv Exp Med Biol 2001;493:207-214.
42. Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res 2002;67:829-836.
43. Chuchawankul S, Shima M, Buckley NE, Hartmann CB, McCoy KL. Role of cannabinoid receptors in inhibiting macrophage costimulatory activity. Int Immunopharmacol 2004;4:265-278.
44. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005;7:E625-E654.
45. Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003;126:2191-2202.
46. Docagne F, Muneton V, Clemente D, et al. Excitotoxicity in a chronic model of multiple sclerosis: neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol Cell Neurosci 2007;34:551-561.
47. Croxford JL, Pryce G, Jackson SJ, et al. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol 2008;193:120-129.
48. Aso E, Ozaita A, Valdizán EM, et al. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 2008;105:565-572.
49. Butovsky E, Juknat A, Goncharov I, et al. In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol. J Neurochem 2005;93:802-811.
50. D'Souza DC, Pittman B, Perry E, Simen A. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology 2009;202:569-578.
51. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, Lutz B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 2004;19:1691-1698.